biphasic insulin aspart + metformin + pioglitazone

This is a **fixed-dose combination therapy** comprising biphasic insulin aspart, metformin, and pioglitazone, used for the management of type 2 diabetes mellitus. **Biphasic insulin aspart** (commonly designated as BIAsp 30) consists of 30% rapid-acting insulin aspart and 70% intermediate-acting insulin aspart, providing both prandial and basal insulin coverage. **Metformin** is a biguanide that reduces hepatic glucose production and increases insulin sensitivity. **Pioglitazone** is a thiazolidinedione that enhances insulin sensitivity via activation of the peroxisome proliferator-activated receptor gamma (PPARγ). When used in combination, these agents target different pathophysiological defects of type 2 diabetes: insulin resistance (metformin, pioglitazone), impaired insulin secretion (insulin aspart), and excessive hepatic glucose output (metformin), providing additive or synergistic glycemic control. Clinical studies show that adding biphasic insulin aspart to optimized regimens of metformin and pioglitazone can further lower HbA1c and improve glycemic outcomes in patients with T2DM inadequately controlled on oral agents alone[3]. No unique brand or code name for a single three-drug, fixed-dose product is identified in public sources.